Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: Evidence for redundancy with cyclin E

Cell Cycle

Volumn 9, Issue 4, 2010, Pages 820-828

  Gumina, Maria R ^a   Xu, Chenjia ^a   Chiles, Thomas C ^a  

^a BOSTON COLLEGE   (United States)

Author keywords

Cdk4; Cell cycle; Cyclin D3; Cyclin E; Diffuse large B cell lymphoma

Indexed keywords

2 BROMO 12,13 DIHYDRO 5H INDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE 5,7 (6H) DIONE; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; 2 BROMO 12,13 DIHYDRO 5 INDOLO(2,3 A)PYRROLO(3,4 C)CARBAZOLE 5,7(6H) DIONE; 2-BROMO-12,13-DIHYDRO-5-INDOLO(2,3-A)PYRROLO(3,4-C)CARBAZOLE-5,7(6H)-DIONE; CARBAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; GENETICS; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

CARBAZOLES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D3; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; G1 PHASE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 77953162429     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.4.10783     Document Type: Article

References (47)

1. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501-12.
2. Besson A, Dowdy SF, Roberts JM. CDK inhibitors: Cell cycle regulators and beyond. Dev Cell 2008; 14:159-69. (Pubitemid 351189186)
3. Ho A, Dowdy SF. Regulation of G(1) cell cycle progression by oncogenes and tumor suppressor genes. Curr Opin Genet Dev 2002; 12:47-52.
4. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 2006; 24:1770-83.
5. 1/S cyclin-dependent kinases. J Biol Chem 1997; 272:12738-46.
6. 1/S transition and high abundance in quiescent tissues suggest a dual role in proliferation and differentiation. Oncogene 1998; 17:1027-37.
7. Lam EW, Glassford J, Banerji L, Thomas NS, Sicinski P, Klaus GG. Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem 2000; 275:3479-84. (Pubitemid 30083056)
8. Solvason N, Wu WW, Parry D, Mahony D, Lam EWF, Glassford J, et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol 2000; 12:631-8. (Pubitemid 30248896)
9. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004; 18:2699-711.
10. Kozar K, Sicinski P. Cell cycle progression without cyclin D-CDK4 and cyclin D-CDK6 complexes. Cell Cycle 2005; 4:388-91. (Pubitemid 41359721)
11. Kozar K, Ciemerych MA, Rebel V, Shigematsu H, Zagozdzon A, Sicinska E, et al. Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004; 118:477-91. (Pubitemid 39485667)
12. Santamaria D, Ortega S. Cyclins and CDKS in development and cancer; lessons from genetically modified mice. Front Biosci 2006; 11:1164-88. (Pubitemid 43253468)
13. Sánchez-Beato M, Sánchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101:1220-35. (Pubitemid 36182489)
14. INK4a. Leukemia 2000; 14:898-904.
15. Sánchez-Beato M, Camacho FI, Martínez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression, p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999; 94:765-72. (Pubitemid 29323891)
16. Al-Assar O, Rees-Unwin KS, Menasce LP, Hough RE, Goepel JR, Hammond DW, et al. Transformed diffuse large B-cell lymphomas with gains of the discontinuous 12q12-14 amplicon display concurrent deregulation of CDK2, CDK4 and GADD153 genes. Br J Haematol 2006; 133:612-21. (Pubitemid 43742775)
17. Sonoki T, Harder L, Horsman DE, Karran L, Taniguchi I, Willis TG, et al. Cyclin D3 is a target gene of t(6;14) (p21.1;q32.3) of mature B-cell malignancies. Blood 2001; 98:2837-44.
18. Kasugai Y, Tagawa H, Kameoka Y, Morishima Y, Nakamura S, Seto M. Identification of CCND3 and BYSL as candidate targets for the 6p21 amplification in diffuse large B-cell lymphoma. Clin Canc Res 2005; 11:8265-72. (Pubitemid 41746936)
19. Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 albation. Nature 2001; 411:1017-21. (Pubitemid 32612319)
20. Yu Q, Sicinska E, Geng Y, Ahnström M, Zagozdzon A, Kong Y, et al. Requirement for CDK4 kinase function in breast cancer. Cancer Cell 2006; 9:23-32. (Pubitemid 43069508)
21. Reddy HK, Mettus RV, Rane SG, Grana X, Litvin J, Reddy EP. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res 2005; 65:10174-8. (Pubitemid 41743706)
22. Landis MW, Pawlyk BS, Li T, Sicinski P, Hinds PW. Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell 2006; 9:13-22. (Pubitemid 43069507)
23. Suzuki R, Kuroda H, Komatsu H, Hosokawa Y, Kagami Y, Ogura M, et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia 1999; 13:1335-42. (Pubitemid 29429759)
24. The Non-Hodginkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89:3909-18.
25. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-11. (Pubitemid 30082188)
26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-47. (Pubitemid 34651353)
27. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V, et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106:3183-9. (Pubitemid 41565917)
28. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res 2002; 8:729-33. (Pubitemid 34742101)
29. Mehra S, Messner M, Minden M, Chaganti RSK. Molecular cytogenetic characterization of non-hodgkin lymphoma cell line. Genes Chrom Cancer 2002; 33:225-34. (Pubitemid 34130928)
30. Faber AC, Chiles TC. Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphoma. Cell Cycle 2007; 6:2982-9.
31. Ding BB, Yu JJ, Raymond Y-L, Mendez LM, Shaknovich R, Zhang Y, et al. Constitutively activated STAT3 promotes cell proliferation and survial in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111:1515-23. (Pubitemid 351213441)
32. Retzer-Lidl M, Schmid RM, Schneider G. Inhibition of CDK4 impairs proliferation of pancreatic cancer cells and sensitizes towards TRAIL-induced apoptosis via downregulation of surviving. Int J Can 2007; 121:66-75. (Pubitemid 46753852)
33. Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 2001; 276:16617-23. (Pubitemid 37411450)
34. Klier M, Anastasov N, Hermann A, Meindl T, Angermeier D, Raffeld M, et al. Specific lentiviral shRNA-mediated knockdown of cyclin d1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008; 22:2097-105.
35. 1-S phase progression. J Biol Chem 2004; 279:5387-96.
36. Geng Y, Whoriskey W, Park MY, Bronson RT, Medema RH, Li T, et al. Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 1999; 97:767-77.
37. Bowe DB, Kenney NJ, Adereth Y, Maroulakou IG. Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E. Oncogene 2002; 21:291-8.
38. 1 Cell Cycle Arrest despite Constitutive Expression of Cyclin E2 in Ovarian Cancer Cells. Can Res 2009; 69:1-8.
39. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996; 93:15215-20.
40. Tetsu O, McCormick F. Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003; 3:233-45. (Pubitemid 37443879)
41. Martín A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M, et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005; 7:591-8. (Pubitemid 40799251)
42. Kozar K, Sicinski P. Cell cycle progression without cyclin D-cdk4 and cyclin D-ckd6 complexes. Cell Cycle 2005; 4:388-91. (Pubitemid 41359721)
43. Cai D, Latham VM, Zhang X, Shapiro GI. Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells. Can Res 2006; 66:9270-80. (Pubitemid 44521149)
44. Malumbres M, Sotillo R, Santamaría D, Galán J, Cerezo A, Ortega S, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases CDK4 and CDK6. Cell 2004; 118:493-504. (Pubitemid 39485668)
45. Baldassarre G, Belletti B, Bruni P, Boccia A, Trapasso F, Pentimalli F, et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 1999; 104:865-74. (Pubitemid 29536336)
46. Chu CY, Lim RW. Involvement of p27(kip1) and cyclin d3 in the regulation of cdk2 activity during skeletal muscle differentiation. Biochim Biophys Acta 2000; 1497:175-85.
47. Nebreda AR. CDK activation by non-cyclin proteins. Cur Opin in Cell Biol 2006; 18:192-8.